Details for Patent: 11,986,527
✉ Email this page to a colleague
Which drugs does patent 11,986,527 protect, and when does it expire?
Patent 11,986,527 protects BRYHALI and DUOBRII and is included in two NDAs.
This patent has twenty-six patent family members in nineteen countries.
Drugs Protected by US Patent 11,986,527
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | ⤷ Subscribe | ||||
| Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,986,527
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011345240 | ⤷ Subscribe | |||
| Brazil | 112013012476 | ⤷ Subscribe | |||
| Canada | 2817524 | ⤷ Subscribe | |||
| Canada | 3055328 | ⤷ Subscribe | |||
| China | 103228281 | ⤷ Subscribe | |||
| European Patent Office | 2643002 | ⤷ Subscribe | |||
| European Patent Office | 4233838 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
